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Gamma-glutamyl transferase activity increases in
prehypertensive patients
Özlem KARAKURT1, Göksel ÇAĞIRCI2, Neslihan Ebru ERYAŞAR2

Aim: To investigate the association between serum gamma-glutamyl transferase (gamma-glutamyl transpeptidase,
GGT) levels and prehypertension in a nationally representative sample of Turkish adults. GGT is an enzyme present
in serum and most cell surfaces. It is used as an oxidative stress marker. Increased serum GGT levels are implicated
in increased blood pressure and the progression of hypertension. GGT may also have a role in the pathogenesis of
cardiovascular disease, diabetes mellitus, obstructive sleep apnea syndrome, and metabolic syndrome.
Materials and methods: Prehypertension was identified as systolic blood pressure ranging from 120 to 139 mmHg or
diastolic blood pressure ranging from 80 to 89 mmHg. Enrolled in this study were 23 female and 45 male patients in the
prehypertensive group (Group 1; mean age of 44.6 ± 11.2 years) and 25 female and 43 male patients in the normotensive
group (Group 2; mean age of 43.3 ± 7.0 years). The serum GGT activity of these patients was measured.
Results: The mean GGT activities were significantly higher in the prehypertension group than in the control group
(24.33 and 18.85 U/L, respectively; P < 0.001).
Conclusion: Elevated GGT levels in prehypertensive individuals support the idea that these patients are under increased
oxidative stress. Even in the prehypertensive stage, it is essential to manage strict cardiovascular risk factor modifications.
Key words: GGT, prehypertension, cardiovascular

Gama-glutamil transferaz aktivitesi prehipertansif hastalarda artar
Amaç: Türk yetişkinleri temsil eden bir ulusal örneklemde serum GGT düzeyleri ile prehipertansiyon arasındaki
ilişkiyi araştırmaktır. Gama-glutamil transferaz (gama-glutamil transpeptidaz, GGT) serum ve bir çok hücre yüzeyinde
bulunan bir enzimdir. GGT bir oksidatif stress belirteci olarak kullanılmaktadır. Artmış serum GGT düzeyleri artmış
kan basıncı ve hipertansiyonun ilerlemesiyle ilişkili bulunmuştur. GGT aynı zamanda kardiyovasküler hastalıkların
patogenezinde , diyabetes mellitusta, obstruktif uyku apnesi sendromunda ve metabolic sendromda rol oynuyor olabilir.
Yöntem ve gereç: Prehipertansiyonu sistolik kan basıncının 120-139 mmHg ya da diyastolik kan basıncının 80-89
mmHg aralığında olması olarak tanımlamıştır. 23 kadın ve 45 erkek prehipertansif hasta (Grup 1, ortalama yaş 44,6 ±
11,2 yıl), 25 kadın ve 43 erkek normotansif hasta (Grup 2, ortalama yaş 43,3 ± 7,0 yıl) çalışmaya alındı. Bu hastalarda
serum GGT aktivitesi ölçüldü.
Bulgular: Prehipertansif grupta control grubuna göre ortalama GGT aktivitesi anlamlı olarak yüksekti (24,33 karşın
18.85 U/L, P < 0,001, sırasıyla).
Sonuç: Prehipertansif bireylerdeki artmış GGT düzeyi bu hastaların artmış oksidatif stress altında olduğu düşüncesini
desteklemektedir. Prehipertansif evrede bile sıkı kardiyovasküler risk faktörü kontrolü sağlamak çok önemli
görünmektedir.
Anahtar sözcükler: GGT, prehipertansiyon, kardiyovasküler
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Introduction
Glutathione (L-g-glutamyl-L-cysteinylglycine)
is the main antioxidant in mammalian cells and is a
ubiquitous thiol-containing tripeptide, which plays
a central role in cell biology (1). Gamma-glutamyl
transferase
(gamma-glutamyl
transpeptidase,
GGT) is an enzyme present in serum and most cell
surfaces (2). It is involved in glutathione metabolism
by transferring the glutamyl moiety to a variety of
acceptor molecules including water, some of the
L-amino acids, and peptides. This reaction produces
cysteinyl-glycine moieties, which are usually taken
within the intracellular milieu by the action of
membrane dipeptidases as precursors for glutathione
resynthesis (1). GGT is used as an oxidative stress
marker (3). One of the suggested mechanisms for
this association is increased transport of glutathione
into cells by increased GGT activity, to maintain high
intracellular antioxidant glutathione levels in order
to compensate for the oxidative stress (4,5). Increased
serum GGT levels are implicated in increased blood
pressure and the progression of hypertension (4-7).
Lee et al. demonstrated that serum GGT is a strong
predictor of incident diabetes and hypertension, even
within a range regarded as physiologically normal, in
the CARDIA study (4). GGT may also have a role in
the pathogenesis of cardiovascular disease, diabetes
mellitus, obstructive sleep apnea syndrome, and
metabolic syndrome (8-14).
The Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High
Blood Pressure (JNC7) identified prehypertension
as systolic blood pressure ranging from 120 to 139
mmHg or diastolic blood pressure ranging from 80
to 89 mmHg, and also as a predictor for developing
hypertension (15). Shankar et al. adduced that higher
serum GGT levels are associated with prehypertension
in the US adult population (5). In this context, we
examined the association between serum GGT levels
and prehypertension in a nationally representative
sample of Turkish adults.
Materials and methods
Patients
This case-control study was performed at the
Ministry of Health Dışkapı Yıldırım Beyazıt Research
976

and Educational Hospital Cardiology Clinic from
January 2007 to August 2008. The participants enrolled
in the study were selected from among the patients
admitted to the cardiology polyclinic. Enrolled in
the study were 23 female and 45 male patients in the
prehypertensive group (Group 1; mean age of 44.6 ±
11.2 years) and 25 female and 43 male patients in the
normotensive group (Group 2; mean age of 43.3 ± 7.0
years). Exclusion criteria were hypertension history,
use of antihypertensive medication, renal failure,
thyroid disorders, congestive heart failure, cirrhosis
of the liver, liver tumors, hepatitis, use of hepatotoxic
drugs or oral contraceptives, previous myocardial
infarction or coronary artery bypass graft operation,
coronary artery disease history, obstructive sleep
apnea syndrome, biliary obstruction, alcohol abuse,
and serum levels more than 2-fold the upper limit
of the reference range of hepatic enzymes. For
each subject, seated systolic and diastolic blood
pressures were measured 3 times using a mercury
sphygmomanometer according to the American
Heart Association and JNC7 recommendations, and
the 3 measurements were averaged. Prehypertension
was defined as systolic blood pressure 120-139 mmHg
or diastolic blood pressure 80-89 mmHg, based
on JNC7 criteria. The hospital’s ethics committee
approved the study and all patients gave informed
written consent.
Echocardiographic evaluation
All patients underwent complete 2-dimensional
transthoracic echocardiographic and Doppler
studies in the left lateral decubitis position, from
multiple windows, to exclude valvular pathologies
and heart failure. A GE Vivid 3 echocardiograph
was used. Echocardiographic measurements were
performed according to the recommendations of
the American Society of Echocardiography and
studies were recorded on compact disks for storage.
Left ventricle volumes and ejection fractions were
obtained by the modified biplane Simpson method.
The left atrium, left ventricle end-diastolic and endsystolic, and aortic root dimensions were measured
from the parasternal long axis view, and the mitral
early diastolic flow (E) velocity and late diastolic
flow (A) velocity, deceleration time, ejection time,
isovolumetric relaxation time, and isovolumetric
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contraction time were measured from the apical
4-chamber view.
Blood tests
Venous blood samples were obtained from an
antecubital vein after a 12-h overnight fast.
Serum GGT, fasting glucose, low-density
lipoprotein cholesterol, high-density lipoprotein
cholesterol,
triglyceride,
and
creatinine
concentrations were measured at 37 °C with an
automatic analyzer.
Statistical analysis
The statistical analysis was performed using SPSS
for Windows. Categorical data were presented as
absolute values and percentages, whereas continuous
data were summarized as mean values ± SD.
Chi-square and Fisher’s exact tests were used for
comparison of categorical variables, as appropriate.
Comparison of continuous variables was performed
by means of Student’s t-test or the Wilcoxon ranksum test, as appropriate. P < 0.05 was considered
statistically significant.

Results
The baseline clinical characteristics of 156
patients are summarized in Table 1. There was
no statistically significant difference for age, sex,
smoking, familial coronary artery disease history,
heart rate, or body mass index between the
groups. Group 2 normotensive patients had lower
systolic and diastolic blood pressure than Group 1
prehypertensive patients (systolic blood pressure:
112.9 ± 7.0 vs. 130.8 ± 1.8 mmHg consecutively, P <
0.001; diastolic blood pressure: 75.5 ± 6.1 vs. 81.9 ±
3.2 mmHg consecutively; P < 0.001).
Regarding the echocardiographic evaluations,
results were similar between the groups for the left
atrium diameter, left ventricle ejection fraction, and
E and A velocity of mitral inflow with pulsed-wave
Doppler and isovolumetric relaxation time (Table 2).
Serum total cholesterol, high-density lipoprotein,
low-density lipoprotein, triglyceride, blood glucose,
and creatinine levels were similar between the groups
(Table 3). Mean GGT activities were significantly
higher in the prehypertension group than in the

Table 1. Demographic characteristics of the study participants.
Group 1
(N = 78)

Group 2
(N = 78)

P-value

Age (years)

44.6 ± 11.2

43.3 ± 7.0

0.382

Male gender

45 (57.7%)

43 (55.1%)

0.747

Smoking

29 (37.2%)

27 (34.6%)

0.739

Dyslipidemia

9 (11.5%)

8 (10.3%)

0.797

Family history of cardiovascular disease

14 (17.9%)

12 (15.4%)

0.667

Systolic blood pressure (mmHg)

130.8 ± 1.8

112.9 ± 7.0

<0.001

Diastolic blood pressure (mmHg)

81.9 ± 3.2

75.5 ± 6.1

<0.001

Height (cm)

166.8 ± 9.0

167.4 ± 8.5

0.668

Weight (kg)

76.7 ± 10.7

74.4 ± 12.8

0.227

Body mass index

27.9 ± 4.0

27.0 ± 4.3

0.148

Heart rate (beats/min)

79.0 ± 10.4

80.2 ± 10.0

0.483
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Table 2. Echocardiographic parameters of the study participants.
Group 1

Group 2

P-value

LVEF (%)

64.9 ± 3.5

65.7 ± 4.5

0.204

LAD (cm)

3.52 ± 0.25

3.46 ± 0.32

0.196

E (cm/s)

0.80 ± 0.1

0.82 ± 0.2

0.304

A (cm/s)

0.64 ± 0.1

0.66 ± 0.2

DT (ms)

191.9 ± 25.2

188.9 ± 16.8

0.409
0.382

87.4 ± 9.9

85.6 ± 9.4

IVRT (ms)

0.243

LVEF: Left ventricular ejection fraction, LAD: left atrial dimension, E: early diastolic flow, A: atrial contraction signal,
DT: deceleration time, IVRT: isovolumic relaxation time.
Table 3. Comparison of laboratory parameters between groups.
Group 1
(N = 78)

Group 2
(N = 78)

P-value

Total cholesterol (mg/dL)

185.7 ± 19.9

182.8 ± 35.4

0.526

Triglyceride (mg/dL)

154.5 ± 69.0

153.2 ± 104.5

0.924

High-density lipoprotein (mg/dL)

43.4 ± 8.9

44.7 ± 12.9

0.442

Low-density lipoprotein (mg/dL)

112.7 ± 30.2

107.8 ± 23.5

0.258

Fatigue blood glucose (mg/dL)

92.9 ± 20.0

93.8 ± 18.2

0.766

Creatinine (mg/dL)

0.9 ± 0.1

0.8 ± 0.2

0.090

Uric acid (mg/dL)

4.7 ± 1.1

4.5 ± 1.2

0.197

GGT

24.3 ± 6.1

18.8 ± 3.7

<0.001

control group (24.33 and 18.85 U/L, respectively; P
< 0.001) (Figure). The GGT level was not correlated
with any clinical or laboratory parameters.
Discussion
This study demonstrated an increased serum
GGT activity in prehypertensive patients compared
to normotensive subjects. In recent years, GGT
activity has been accepted as a valuable marker of
oxidative stress status. Glutathione (L-g-glutamylL-cysteinylglycine) is a ubiquitous thiol-containing
tripeptide, which plays a central role in cell biology
and is the main antioxidant in mammalian cells. It is
implicated in the cellular defense against xenobiotics
978

and naturally occurring deleterious compounds,
such as free radicals and hydroperoxides. Glutathione
status is a highly sensitive indicator of cell functionality
and viability (1). In humans, glutathione depletion is
linked to a number of disease states, including cancer
and neurodegenerative and cardiovascular diseases
(16).
GGT is an enzyme present in serum and most cell
surfaces. It is found in the epithelia of tissues that are
extensively involved in transport, for example the
liver, bile ducts, nephron, choroid plexus, jejunum,
epididymis, and ciliary bodies (2). Although GGT
can be produced by every tissue, because glucose
moieties linked to the enzyme display differences
between tissues, only GGT produced by the liver
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can be detected in serum (17). GGT is responsible
for initiating extracellular catabolism of glutathione,
the main antioxidant in mammalian cells, and
for the transfer of amino acids across the cellular
membrane. It is involved in glutathione metabolism
by transferring the glutamyl moiety to a variety of
acceptor molecules including water, some of the
L-amino acids, and peptides. This reaction produces
cysteinyl-glycine moieties, which are usually taken
within the intracellular milieu by the action of
membrane dipeptidases as precursors for glutathione
resynthesis (1). Since serum GGT mainly comes
from the biliary system, it is a sensitive test for liver
function, especially in biliary obstruction and alcohol
abuse. However, there are many other reasons for
an increased serum GGT level, such as congestive
heart failure, cirrhosis of the liver, restricted blood
flow to the liver, restricted venous outflow from the
liver (like Budd-Chiari syndrome), necrosis of the
liver, liver tumors, hepatitis, and hepatotoxic drugs.
GGT is also used as an oxidative stress marker
(3). One of the suggested mechanisms for this
association is the increased transport of glutathione
into cells by increased GGT activity, to maintain
a high intracellular antioxidant glutathione level
in order to be able to compensate for the oxidative
stress (4, 5). Lee et al. demonstrated that serum
C-reactive protein levels, a marker of inflammation,
positively correlated with GGT levels (18). Increased

serum GGT levels are implicated in increased blood
pressure and the progression of hypertension (4-7).
Lee et al. demonstrated that serum GGT is a strong
predictor of incident diabetes and hypertension,
even within a range regarded as physiologically
normal, in the CARDIA study (2). GGT may have
a role in the pathogenesis of cardiovascular disease,
diabetes mellitus, obstructive sleep apnea syndrome,
and metabolic syndrome (8-14). Strong positive
associations between serum GGT level and body
mass index, smoking, total lipoprotein and highdensity lipoprotein, serum cholesterol, uric acid,
serum triglycerides, heart rate, antihypertensive
medication, use of oral contraceptives, and
menopause have been shown (6,19,20). Active GGT
has been found within atherosclerotic cerebral,
carotid, and coronary plaques from autoptic studies
and surgical endarterectomy materials. GGT was
colocalized with oxidized density lipoproteins and
CD68+ foam cells in these lesions (21-23). To explain
the possible association between GGT and the
inflammatory process, it should also be considered
that GGT has a key role in the interconversion of
the glutathione-containing inflammatory mediator
leukotriene C4 into leukotriene D4 (24).
Conclusion and limitations
The main limitation of this study was the small
number of patients. Results should be confirmed
with larger studies.
We demonstrated that the GGT level in
prehypertensive patients was higher than that
of normotensive individuals (24.33 vs. 18.85
U/L, respectively; P < 0.001), pointing to the
prehypertension-GGT relationship. Elevated GGT
levels in prehypertensive individuals support the
idea that these patients are under increased oxidative
stress. These findings confirm the need for strict
monitoring and follow-up of cardiovascular diseases
and diabetes in these patients. Even before people
are diagnosed as hypertensive, oxidative damage
progresses rapidly and begins to harm many of
the organs. Even in the prehypertensive stage, it is
essential to manage strict cardiovascular risk factor
modifications.
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